Overview

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the pharmacokinetics, pharmacodynamics, and safety of single and multiple doses of armodafinil (50, 100, and 150 mg/day) in children and adolescents with excessive sleepiness associated with narcolepsy.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries

Treatments:

Armodafinil
Modafinil